| Goldbelt raven
LLC was selected because of their
exceptional performance in the Infections
Disease/Biological Product Development
Support. The contract is an initial 5year
contract with an award term period of an
additional 5 years. This project management
office is a major acquisition program
subject to the DOD 5000 acquisition
regulations and is a direct report to the
Joint Program Executive Office for Chemical
Biological Defense.
The Chemical
Biological Medical Systems Joint Management
Office (CBMS-JPMO) is responsible for the
development, procurement, fielding, and
sustaining of premier medical protection and
treatment capabilities against chemical and
biological warfare agents. The products are
all submitted through the U.S. Food and Drug
Administration (FDA) licensing or approval
processes. The CBMS-JPMO is comprised of an
headquarters and support element and two
Joint Product Management Offices: the Joint
Vaccine Acquisition Program (JVAP) and the
Medical Identification and Treatment Systems
(MITS).
The mission of
the Joint Vaccine Acquisition Program (JVAP)
is to develop, produce and stockpile FDA
licensed vaccine products to protect the
fighter against biological warfare agents.
JVAP consolidates the Department of
Defense's efforts for the advanced development,
testing, FDA licensing, production and
storage of Biological Defense
vaccines.
The Medical
Identification and Treatment Systems (MITS)
centrally manages the development,
acquisition and fielding of products used
for the prophylaxis, treatment, and
diagnosis of chemical and biological warfare
agent exposure in U.S. Service members. MITS
products range from specific biological
warfare agent exposure, to drugs which will
prevent or mitigate the action of chemical
or biological agents
|
